New hope for aggressive brain tumors: drug delivered directly to the brain
NCT ID NCT01269853
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tests whether giving the drug bevacizumab (Avastin) directly into the brain's arteries, repeated over time, is safe and effective for people with recurrent glioblastoma or anaplastic astrocytoma. The approach aims to bypass the blood-brain barrier, which often blocks standard intravenous treatments. About 54 adults whose tumors have returned after initial therapy will receive the drug this way, with researchers tracking tumor response and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lenox Hill Brain Tumor Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (Avastin)
What this could lead to
If it works, this could offer a more effective way to deliver bevacizumab directly to brain tumors, potentially extending survival for patients with recurrent glioblastoma or anaplastic astrocytoma.
What could go wrong
This is an early phase 1/2 trial with only 54 participants, so results may not apply broadly. The procedure involves infusing the drug into brain arteries, which carries risks like bleeding or stroke.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.